455 related articles for article (PubMed ID: 32486345)
41. Plaque Size Is Decreased but M1 Macrophage Polarization and Rupture Related Metalloproteinase Expression Are Maintained after Deleting T-Bet in ApoE Null Mice.
Tsaousi A; Hayes EM; Di Gregoli K; Bond AR; Bevan L; Thomas AC; Newby AC
PLoS One; 2016; 11(2):e0148873. PubMed ID: 26886778
[TBL] [Abstract][Full Text] [Related]
42. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome.
Peeters W; Moll FL; Vink A; van der Spek PJ; de Kleijn DP; de Vries JP; Verheijen JH; Newby AC; Pasterkamp G
Eur Heart J; 2011 Sep; 32(18):2314-25. PubMed ID: 21289041
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
George SJ
Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
[TBL] [Abstract][Full Text] [Related]
44. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
Rouis M
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):541-8. PubMed ID: 16503874
[TBL] [Abstract][Full Text] [Related]
45. Extreme Levels of Air Pollution Associated With Changes in Biomarkers of Atherosclerotic Plaque Vulnerability and Thrombogenicity in Healthy Adults.
Xu H; Wang T; Liu S; Brook RD; Feng B; Zhao Q; Song X; Yi T; Chen J; Zhang Y; Wang Y; Zheng L; Rajagopalan S; Li J; Huang W
Circ Res; 2019 Mar; 124(5):e30-e43. PubMed ID: 30661461
[TBL] [Abstract][Full Text] [Related]
46. Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes.
Edsfeldt A; Gonçalves I; Grufman H; Nitulescu M; Dunér P; Bengtsson E; Mollet IG; Persson A; Nilsson M; Orho-Melander M; Melander O; Björkbacka H; Nilsson J
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2143-50. PubMed ID: 25035341
[TBL] [Abstract][Full Text] [Related]
47. Relation between TLR4/NF-κB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability.
Gargiulo S; Gamba P; Testa G; Rossin D; Biasi F; Poli G; Leonarduzzi G
Aging Cell; 2015 Aug; 14(4):569-81. PubMed ID: 25757594
[TBL] [Abstract][Full Text] [Related]
48. Biochemical and Biological Attributes of Matrix Metalloproteinases.
Cui N; Hu M; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
[TBL] [Abstract][Full Text] [Related]
49. Distribution of Matrix Metalloproteinases in Human Atherosclerotic Carotid Plaques and Their Production by Smooth Muscle Cells and Macrophage Subsets.
Jager NA; Wallis de Vries BM; Hillebrands JL; Harlaar NJ; Tio RA; Slart RH; van Dam GM; Boersma HH; Zeebregts CJ; Westra J
Mol Imaging Biol; 2016 Apr; 18(2):283-91. PubMed ID: 26377769
[TBL] [Abstract][Full Text] [Related]
50. Yellow wine polyphenolic compounds inhibit matrix metalloproteinase-2, -9 expression and improve atherosclerotic plaque in LDL-receptor-knockout mice.
Zhai X; Chi J; Tang W; Ji Z; Zhao F; Jiang C; Lv H; Guo H
J Pharmacol Sci; 2014; 125(2):132-41. PubMed ID: 24859779
[TBL] [Abstract][Full Text] [Related]
51. Matrix metalloproteinases in cardiovascular disease.
Liu P; Sun M; Sader S
Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):25B-30B. PubMed ID: 16498509
[TBL] [Abstract][Full Text] [Related]
52. Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice?
Matusik P; Guzik B; Weber C; Guzik TJ
Thromb Haemost; 2012 Sep; 108(3):443-56. PubMed ID: 22872109
[TBL] [Abstract][Full Text] [Related]
53. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery.
Pasterkamp G; Schoneveld AH; Hijnen DJ; de Kleijn DP; Teepen H; van der Wal AC; Borst C
Atherosclerosis; 2000 Jun; 150(2):245-53. PubMed ID: 10856516
[TBL] [Abstract][Full Text] [Related]
54. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
55. Matrix metalloproteinases in atherothrombosis.
Bäck M; Ketelhuth DF; Agewall S
Prog Cardiovasc Dis; 2010; 52(5):410-28. PubMed ID: 20226959
[TBL] [Abstract][Full Text] [Related]
56. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques.
Schäfers M; Schober O; Hermann S
J Nucl Med; 2010 May; 51(5):663-6. PubMed ID: 20439506
[TBL] [Abstract][Full Text] [Related]
57. [Pathophysiological bases of unstable coronary syndrome].
Waltenberger J
Herz; 2001 Apr; 26 Suppl 1():2-8. PubMed ID: 11349622
[TBL] [Abstract][Full Text] [Related]
58. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
59. Increased proteolytic cleavage of osteoglycin is associated with a stable plaque phenotype and lower risk of cardiovascular events.
Al-Sharify D; Nielsen SH; Matthes F; Tengryd C; Sun J; Genovese F; Karsdal MA; Nilsson J; Goncalves I; Edsfeldt A
Atherosclerosis; 2022 Aug; 355():8-14. PubMed ID: 35850021
[TBL] [Abstract][Full Text] [Related]
60. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes.
Goncalves I; Bengtsson E; Colhoun HM; Shore AC; Palombo C; Natali A; Edsfeldt A; Dunér P; Fredrikson GN; Björkbacka H; Östling G; Aizawa K; Casanova F; Persson M; Gooding K; Strain D; Khan F; Looker HC; Adams F; Belch J; Pinnoli S; Venturi E; Kozakova M; Gan LM; Schnecke V; Nilsson J;
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1723-31. PubMed ID: 25953645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
